TKNO
NASDAQAlpha Teknova Inc.
Price$4.63-0.07 (-1.38%)
01:30 PM07:45 PM
News · 26 weeks17-33%
2025-12-142026-06-07
Mix1090d
- SEC Filings5(50%)
- Insider3(30%)
- Earnings2(20%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Vos Alexander4 - Alpha Teknova, Inc. (0001850902) (Issuer)
- INSIDERSEC Form 4 filed by Director Robertson Brett4 - Alpha Teknova, Inc. (0001850902) (Issuer)
- INSIDERSEC Form 4 filed by Director Demski Martha J4 - Alpha Teknova, Inc. (0001850902) (Issuer)
- SECAlpha Teknova Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Alpha Teknova, Inc. (0001850902) (Filer)
- SECSEC Form 10-Q filed by Alpha Teknova Inc.10-Q - Alpha Teknova, Inc. (0001850902) (Filer)
- SECAlpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics8-K - Alpha Teknova, Inc. (0001850902) (Filer)
- PRTeknova Reports First Quarter 2026 Financial ResultsFirst quarter 2026 total revenue was $11.1 million, up 13% over the same quarter prior yearCompany reaffirms 2026 revenue guidance of $42-44 million HOLLISTER, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2026. "We had a great start to 2026," said Stephen Gunstream, President and Chief Executive Officer at Teknova. "The substantial investments we've made since 2021, combined with an improved market backdrop, p
- PRTeknova to Report First Quarter 2026 Financial Results on May 6, 2026HOLLISTER, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2026, on Wednesday, May 6, 2026, following the close of market. Teknova will host a webcast and conference call on Wednesday, May 6, 2026, beginning at 6:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to p
- SECSEC Form DEFA14A filed by Alpha Teknova Inc.DEFA14A - Alpha Teknova, Inc. (0001850902) (Filer)
- SECSEC Form DEF 14A filed by Alpha Teknova Inc.DEF 14A - Alpha Teknova, Inc. (0001850902) (Filer)
- INSIDERSEC Form 4 filed by General Counsel and CCO Terrill Damon4 - Alpha Teknova, Inc. (0001850902) (Issuer)
- INSIDERChief Financial Officer Lowell Matthew bought $87,616 worth of shares (40,000 units at $2.19), increasing direct ownership by 31% to 168,376 units (SEC Form 4)4 - Alpha Teknova, Inc. (0001850902) (Issuer)
- INSIDERPresident and CEO Gunstream Stephen bought $55,801 worth of shares (26,000 units at $2.15), increasing direct ownership by 11% to 269,497 units (SEC Form 4)4 - Alpha Teknova, Inc. (0001850902) (Issuer)
- SECSEC Form 10-K filed by Alpha Teknova Inc.10-K - Alpha Teknova, Inc. (0001850902) (Filer)
- SECAlpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Alpha Teknova, Inc. (0001850902) (Filer)
- PRTeknova Reports Fourth Quarter and Full Year 2025 Financial ResultsFull year 2025 total revenue was $40.5 million, up 7% year-over-year and in line with guidanceFourth quarter 2025 total revenue was $10.0 million, up 8% over the same quarter prior yearCompany provides 2026 revenue guidance of $42-44 million HOLLISTER, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the fourth quarter and full year ended December 31, 2025. "After another successful year of disciplined execution against our strategic objectives,
- PRTeknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026HOLLISTER, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, following the close of market. Teknova will host a webcast and conference call on Thursday, February 26, 2026, beginning at 5:30 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this l
- SECSEC Form 10-Q filed by Alpha Teknova Inc.10-Q - Alpha Teknova, Inc. (0001850902) (Filer)
- SECAlpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Alpha Teknova, Inc. (0001850902) (Filer)
- PRTeknova Reports Third Quarter 2025 Financial ResultsThird quarter 2025 total revenue was $10.5 million, up 9% from prior yearAchieves five consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2025. "We had a strong third quarter, our fifth consecutive quarter of year-over-year revenue growth, despite a very challenging funding backdrop for smal
- PRTeknova to Report Third Quarter 2025 Financial Results on November 6, 2025HOLLISTER, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, November 6, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would l
- SECSEC Form 10-Q filed by Alpha Teknova Inc.10-Q - Alpha Teknova, Inc. (0001850902) (Filer)
- SECAlpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Alpha Teknova, Inc. (0001850902) (Filer)
- PRTeknova Reports Second Quarter 2025 Financial ResultsSecond quarter 2025 total revenue was $10.3 million, up 7% from prior yearAchieves four consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2025. "Despite continued uncertainty in the macroenvironment, we delivered another strong quarter of results, with improvements in both the top and bottom li
- PRTeknova to Report Second Quarter 2025 Financial Results on August 7, 2025HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, August 7, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to p
TKNO FAQ
6 questionsWhere does TKNO stock trade?
Alpha Teknova Inc. (TKNO) is listed on NASDAQ.What sector and industry is TKNO in?
Alpha Teknova Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did Alpha Teknova Inc. go public?
Alpha Teknova Inc. (TKNO) completed its IPO in 2021.What are analysts saying about TKNO?
Alpha Teknova Inc. has had 7 recent analyst actions on file. The most recent action was from Stephens: Overweight with a $800.00 price target on 2025-07-22. Recent price targets range from $800.00 to $2700.00.What companies are similar to TKNO?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), ORKA (Oruka Therapeutics Inc.), NNNN (Anbio Biotechnology). Compare TKNO side-by-side with any of them on Quantisnow.How can I track TKNO on Quantisnow?
Quantisnow aggregates Alpha Teknova Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TKNO to receive live email and push alerts on every new disclosure.